Year after year, the Dilon team attends Miami Breast to meet with breast surgeons, medical and radiation oncologists and the institutions and innovators that support them.
The care of breast cancer patients is rapidly changing and we want Miami Breast 2018 attendees to know that Dilon’s first FDA approved device, the MarginProbe, is contributing to improving patient outcomes by giving surgeons an effective way to identify intra-operatively residual microscopic cancer and thereby reduce the risk of having to call back patients to tell them their margins were positive and they need a second surgery. As a result, patients care paths are uninterrupted and return to living their lives without the anguish of a second surgery or prolonged treatment. MarginProbe can help healthcare providers better meet their patient needs and reduce unnecessary patient anxiety from questioning “Did we get it all”.
At Miami Breast 2018, March 8th through 11th, we look forward to reconnecting with colleagues and creating new relationships with the surgeons on the front lines of care for breast cancer patients. Stop by our booth T7 in the Luster Gallery to learn more about the MarginProbe!
Sessions that have our attention
- March 8th, 02:10 PM – DCIS: What Is the Evidence for a 2-MM Margin?
- March 8th, 05:00 PM – Pathology Update on Marker Assessment and Grade
- March 9th, 12:15 PM – Breast Cancer 2018: The Patient Perspective
Access the full Miami Breast 2018 conference program here.
If you would like to learn more about MarginProbe and Radiofrequency spectroscopy contact firstname.lastname@example.org to arrange a meeting onsite at Miami Breast 2018 or stop by booth T7 in the Luster Gallerie!